Corrections to an Article By Peter Kennedy, MD

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 7
Volume 5
Issue 7

Oncology News International would like to correct two errors that appeared in Dr. Peter Kennedy's article on space sharing (May 1996, page 12), as part of the Oncology & Managed Care series edited by Dr. Cary Presant.

Oncology News International would like to correct two errors thatappeared in Dr. Peter Kennedy's article on space sharing (May1996, page 12), as part of the Oncology & Managed Care seriesedited by Dr. Cary Presant.

Dr. Kennedy is president and founder of Metropolitan OncologyMedical Group, Inc., Los Angeles. Dr. Armand Bouzaglou, a radiotherapistwho shares space with Dr. Kennedy's group, does not have an exclusivecontract with Dr. Kennedy to provide radiation therapy servicesfor his patients. The editors apologize for these errors.

Articles in this issue
Princess Diana Helps Raise Over $1 Million for Cancer Research
Study Gives Terminal Patients Option: $18,000 or More Treatment
Proven: Colorectal Screening Cuts Deaths 50%
Virtual Colonoscopy Technique Feasible in Detecting Polyps
Trimetrexate Appears Beneficial in Colorectal Cancer
FDA Liaison Program Answers Patients' Questions About Trials
New Company Joins With RPR To Develop Intrabody Technology
More Insurers Covering ABMT, Despite Lack of Efficacy Data
Klausner Requests Funds for Five Important 'Investment Opportunities' in Cancer Research
CDC Says Teen Smoking Still Rising
ThinPrep Pap Test Offers Improved Slide Preparation
Taxotere for Anthracycline Refractory Advanced Breast Cancer
ODAC Recommends Approval of Aredia for Breast Cancer Bone Mets
Hycamtin Approved For Ovarian Cancer
Gemzar for Treatment of Locally Advanced or Metastatic Pancreatic Cancer
Related Videos
A panel of 3 experts on multiple myeloma
A panel of 3 experts on multiple myeloma
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
The toxicity profile of tislelizumab also appears to look better compared with chemotherapy in metastatic esophageal squamous cell carcinoma.
Related Content
Updates in Breast Cancer Care From the 41st Annual Miami Breast Cancer Conference

Updates in Breast Cancer Care From the 41st Annual Miami Breast Cancer Conference

April 15th 2024
Article

Several presentations from the 41st Annual Miami Breast Cancer Conference focused on new and evolving data in the space, according to Neil M. Iyengar, MD.

Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.

Surgeons Talk Key Treatment and Institutional Advances Across Oncology Care

April 15th 2024
Podcast

Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.

Sacituzumab Tirumotecan Shows Early Efficacy in Gastric/GEJ Cancers

Sacituzumab Tirumotecan Shows Early Efficacy in Gastric/GEJ Cancers

April 15th 2024
Article

Sacituzumab tirumotecan elicited responses prominently in the second- and third-line and beyond setting and in those with high TROP2 expression.

Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.

Finding Ways to Break the Mold in GU Oncology

April 8th 2024
Podcast

Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.

Novel CAR T-Cell Therapy Yields Response in R/R Non-Hodgkin Lymphoma

Novel CAR T-Cell Therapy Yields Response in R/R Non-Hodgkin Lymphoma

April 14th 2024
Article

HR001 was found to have an efficacious response for patients with relapsed/refractory non-Hodgkin lymphoma.

72 A Novel Biosignature for Early- Stage Invasive Breast Cancer to Predict Radiotherapy Benefit and Assess Recurrence Risk for Patients Treated With Breast- Conserving Surgery

72 A Novel Biosignature for Early- Stage Invasive Breast Cancer to Predict Radiotherapy Benefit and Assess Recurrence Risk for Patients Treated With Breast- Conserving Surgery

April 13th 2024
Article